Protocol Ledger

NCT05640999 · Phase II · RECRUITING

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

Interventional Phase II clinical trial protocol NCT05640999 sponsored by Canadian Cancer Trials Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-12-19 Enrollment: 393 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05640999
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)393 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05640999
Protocol FieldVerified Registry Value
NCT IdentifierNCT05640999
Consolidated Lead SponsorCanadian Cancer Trials Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment393 participants (ESTIMATED)
Registered Start Date2022-12-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI